YY1 has emerged as a promising target for antitumor therapy in recent years due to its critical role in regulating various hallmarks of cancer, such as tumor cell proliferation, evading programmed cell death, deregulated metabolism, induction of angiogenesis, activation of invasion and metastasis, genome instability, and evading immune system [11,19,20,21], as well as in tumor cell drug resistance [22,23,24]. The gene discussed is YY1; the disease is cancer.